Peter Attia· MD
the field lost its way in this drug based on the wrong biomarker we were using hdlc as a biomarker because we didn't have a better biomarker for c-tep inhibition and so the initial Insight in the biology was right but by having the wrong biomarker and failing to understand the mechanism of that